NEW YORK (GenomeWeb News) – BioMarker Strategies today announced it is being granted a $1.5 million Small Business Innovation Research Phase II award to further develop its companion diagnostic for melanoma.

The grant from the National Cancer Institute will go toward the Baltimore, Md.-based firm's refinement of its PathMap assay and ex vivo protocols developed under a Phase I SBIR contract. The new funding will also support validation of PathMap in human clinical samples, BioMarker Strategies said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.